How do I … manage the platelet transfusion-refractory patient?

Area of Science:

• Hematology
• Immunology
• Transfusion Medicine

Background:

• Platelet transfusion-refractoriness presents a significant clinical and economic challenge, particularly in patients with hematologic malignancies.
• While often nonimmune, refractoriness can stem from alloimmunization to human leukocyte antigens (HLAs) or human platelet antigens (HPAs).
• Management of immune-mediated refractoriness relies on antigen-negative products.

Purpose of the Study:

• To develop and implement a diagnostic and management algorithm for platelet transfusion-refractory patients.
• To prioritize the identification of immune-mediated causes of refractoriness.
• To assess the algorithm's impact on resource utilization and clinical outcomes.

Main Methods:

• Utilized physical platelet cross-matches for initial classification of refractoriness.
• Provided cross-match-compatible inventory for immune-mediated cases.
• Integrated subsequent human leukocyte antigen (HLA) and human platelet antigen (HPA) antibody testing.
• Performed upfront Class I HLA typing of repeat platelet donors for virtual cross-matching and donor recruitment.

Main Results:

• The algorithm identified immune-mediated causes of platelet transfusion-refractoriness.
• Class I HLA typing of donors facilitated identification of antigen-negative units.
• The diagnostic and management algorithm demonstrated initial net cost savings by reducing unnecessary apheresis platelet usage.

Conclusions:

• An integrated algorithm incorporating physical cross-matches, HLA/HPA antibody testing, and donor HLA typing improves clinical management of platelet transfusion-refractory patients.
• This approach leads to overall resource savings within transfusion services.
• Early identification and management of immune-mediated refractoriness are key to optimizing patient care and resource allocation.